pre-update Archives

Blog

Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development

This blog will reflect on 3 things drug developers should pay attention to regarding safety…

CertaraJanuary 24, 2022

Press Coverage

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and…

CertaraJanuary 19, 2022

Video

R Speaks NLME (RsNLME) Overview

This recording shows an overall review of RsNLME using Pirana and an extensive explanation on…

CertaraJanuary 19, 2022

White Paper

The Essential Components of Your Drug’s Biomarker Strategy

CertaraJanuary 14, 2022

On-Demand Webinar

What Oncology Drug Developers Should Expect from the FDA’s Project Optimus

Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This…

CertaraJanuary 13, 2022

On-Demand Webinar

PBPK Modeling of Antibody-Drug Conjugates – Concept and Application

Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…

CertaraJanuary 13, 2022

Blog

When Should I Select an eCTD Vendor for My Regulatory Submission?

As your company moves towards the regulatory submission of a marketing application to a health…

CertaraJanuary 10, 2022

On-Demand Webinar

Certara University Express Webinar: Part 2: Introduction to RsNLME and overview of expanded workflow

Introduction to RsNLME and its capabilities for population PK/PD modeling.

CertaraJanuary 5, 2022

On-Demand Webinar

Certara University Express Webinar: Part 1: Introduction to RsNLME (R speaks NLME)

Introduction to RsNLME and its capabilities for population PK/PD modeling.

CertaraJanuary 5, 2022

Announcement

Certara Acquires Integrated Nonclinical Development Solutions

Expands software portfolio and nonclinical drug development expertise PRINCETON, N.J.— Jan 5, 2022– Certara, Inc.,…

CertaraJanuary 5, 2022

pre-update

Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

R Speaks NLME (RsNLME) Overview

The Essential Components of Your Drug’s Biomarker Strategy

What Oncology Drug Developers Should Expect from the FDA’s Project Optimus

PBPK Modeling of Antibody-Drug Conjugates – Concept and Application

When Should I Select an eCTD Vendor for My Regulatory Submission?

Certara University Express Webinar: Part 2: Introduction to RsNLME and overview of expanded workflow

Certara University Express Webinar: Part 1: Introduction to RsNLME (R speaks NLME)

Certara Acquires Integrated Nonclinical Development Solutions

Newsletter sign up

Quick links

Solutions

Contact